Di Xiao1,2,3, Si-Min Zhang4, Xi Li1,2,3, Ji-Ye Yin1,2,3, Wei-Jing Gong1,2, Yi Zheng5, Xiao-Jing Xu1,2, Xu Lin6, Li-Nong Ji4, Rang-Ru Liu1,2, Qiang Tang7, Wei Zhang1,2,3, Hong-Hao Zhou1,2,3, Xue-Yao Han4, Zhao-Qian Liu1,2,3. 1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China. 2. Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China. 3. Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China. 4. Department of Endocrinology, The People's Hospital of Peking University, Beijing 100044, People's Republic of China. 5. The Maternal & Child Health Hospital of Hunan Province, Changsha 410008, People's Republic of China. 6. Institute of Nutrition Science of Shanghai School for Biological Sciences, Chinese Academy of Sciences, Shanghai 20031, People's Republic of China. 7. Department of Pharmacy, The Huaihua Third People's Hospital, Huaihua 418000, People's Republic of China.
Abstract
AIM: To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS: 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone. Genotyping was done by Illumina GoldenGate Assay. RESULTS: In the discovery stage, 22 SNPs were nominally significant. IL1B rs1143623 (p = 0.011) and EEF1A1P11-RPL7P9 rs10783050 (p = 0.021) were still significantly associated with the relative change of HbA1c in the replication stage. CONCLUSION: IL1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms may contribute to metformin's glucose-lowing efficacy in overweight or obese Chinese T2DM patients.
AIM: To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS: 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone. Genotyping was done by Illumina GoldenGate Assay. RESULTS: In the discovery stage, 22 SNPs were nominally significant. IL1Brs1143623 (p = 0.011) and EEF1A1P11-RPL7P9rs10783050 (p = 0.021) were still significantly associated with the relative change of HbA1c in the replication stage. CONCLUSION:IL1Brs1143623 and EEF1A1P11-RPL7P9rs10783050 polymorphisms may contribute to metformin's glucose-lowing efficacy in overweight or obese Chinese T2DM patients.
Authors: Kimberly Alexander; Yvette P Conley; Jon D Levine; Bruce A Cooper; Steven M Paul; Judy Mastick; Claudia West; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-09-23 Impact factor: 3.612